{
    "Clinical Trial ID": "NCT00022516",
    "Intervention": [
        "INTERVENTION 1: ",
        "  No-CM",
        "  No further chemotherapy following standard adjuvant chemotherapy.",
        "INTERVENTION 2: ",
        "  CM-Maintenance",
        "  12-month CM-maintenance regimen (C, cyclophosphamide 50 mg/day orally continuously and M, methotrexate 2.5 mg twice/day orally days 1 and 2 of every week for 1 year)",
        "  Cyclophosphamide: 50 mg/day orally continuously for 1 year",
        "  Methotrexate: 2.5 mg twice/day orally days 1 and 2 of every week for 1 year"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed stage I, II, or III breast cancer",
        "  T1-3, N0-2, M0",
        "  Patients with sentinel node biopsy positive disease must have undergone axillary dissection",
        "  Tumor must be confined to the breast without detected metastases elsewhere",
        "  T4 disease with minimal dermal invasion allowed",
        "  No T4 disease with ulceration of skin, infiltration of skin (except pathologically minimal dermal involvement), peau d'orange, or inflammatory breast cancer",
        "  No bilateral breast cancer (except in situ carcinoma) or suspicious mass in opposite breast that has not been proven benign",
        "  No distant metastases",
        "  No skeletal pain of unknown cause, elevated alkaline phosphatase, or bone scan showing hot spots that cannot be ruled out as metastases by x-ray, MRI, and/or CT",
        "  Must have undergone prior total mastectomy OR breast-conserving procedure (e.g., lumpectomy, quadrantectomy, or partial mastectomy with negative margins) with radiotherapy planned",
        "  Patients must begin or have begun an approved induction chemotherapy regimen within 8 weeks after definitive surgery",
        "  Negative surgical margins",
        "  Axillary clearance with at least 6 lymph nodes examined OR negative sentinel node biopsy",
        "  Known HER2 status by immunohistochemistry or fluorescence in situ hybridization",
        "  Hormone receptor status:",
        "  Estrogen and progesterone receptor negative",
        "  Less than 10% positive tumor cells by immunohistochemistry",
        "  PATIENT CHARACTERISTICS:",
        "  Age:",
        "Not specified",
        "  Sex:",
        "  Not specified",
        "  Menopausal status:",
        "  Premenopausal, defined as less than 6 months since last menstrual period (LMP) AND no prior bilateral ovariectomy AND not on estrogen replacement (OR under age 50) OR",
        "  Postmenopausal, defined as prior bilateral ovariectomy OR more than 12 months since LMP without prior hysterectomy (OR age 50 and over)",
        "Performance status:",
        "  Not specified",
        "  Life expectancy:",
        "  Not specified",
        "  Hematopoietic:",
        "  WBC greater than 3,000/mm3",
        "  Platelet count greater than 100,000/mm3",
        "  Hepatic:",
        "  See Disease Characteristics",
        "  Bilirubin less than 2.0 mg/dL",
        "  ALT less than 1.5 times upper limit of normal OR AST less than 60 IU/L",
        "  Renal:",
        "  Creatinine less than 1.2 mg/dL",
        "  Other:",
        "  Not pregnant or lactating within the past 6 months",
        "  Fertile patients must use effective barrier contraception",
        "  No other prior or concurrent malignancy except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or contralateral or ipsilateral in situ breast carcinoma",
        "  No psychiatric or addictive disorders that would preclude study",
        "  No non-malignant systemic disease that would preclude study",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy:",
        "  Prior trastuzumab (Herceptin) allowed",
        "  Chemotherapy:",
        "  See Disease Characteristics",
        "  No prior adjuvant or neoadjuvant chemotherapy for breast cancer",
        "  Endocrine therapy:",
        "  No prior endocrine therapy for breast cancer or prevention",
        "  No prior tamoxifen or raloxifene for breast cancer",
        "  Radiotherapy:",
        "  No prior radiotherapy for breast cancer except primary irradiation",
        "  Surgery:",
        "  See Disease Characteristics",
        "  Other:",
        "  No prior preventative therapy for breast cancer"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Disease-free Survival",
        "  Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to the first appearance of one of the following: invasive breast cancer recurrence at local, regional, or distant site, invasive contralateral breast cancer, second (non-breast) invasive cancer, or death without cancer event; or censored at date of last follow-up.",
        "  Time frame: 5-year estimates, reported at a median follow-up of 6.9 years",
        "Results 1: ",
        "  Arm/Group Title: No-CM",
        "  Arm/Group Description: No further chemotherapy following standard adjuvant chemotherapy.",
        "  Overall Number of Participants Analyzed: 539",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  74.7        (70.6 to 78.3)",
        "Results 2: ",
        "  Arm/Group Title: CM-Maintenance",
        "  Arm/Group Description: 12-month CM-maintenance regimen (C, cyclophosphamide 50 mg/day orally continuously and M, methotrexate 2.5 mg twice/day orally days 1 and 2 of every week for 1 year)",
        "  Cyclophosphamide: 50 mg/day orally continuously for 1 year",
        "  Methotrexate: 2.5 mg twice/day orally days 1 and 2 of every week for 1 year",
        "  Overall Number of Participants Analyzed: 542",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  78.1        (74.2 to 81.6)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/0",
        "  Leukopenia 0/0",
        "  Neutropenia 0/0",
        "  Ocular-other 0/0",
        "  Elevated SGPT 0/0",
        "  Arthralgia 0/0",
        "  CNS hemorrhage 0/0",
        "  Neurologic-other 0/0",
        "  Radiation dermatitis 0/0",
        "Adverse Events 2:",
        "  Total: 11/473 (2.33%)",
        "  Leukopenia 2/473 (0.42%)",
        "  Neutropenia 5/473 (1.06%)",
        "  Ocular-other 1/473 (0.21%)",
        "  Elevated SGPT 1/473 (0.21%)",
        "  Arthralgia 1/473 (0.21%)",
        "  CNS hemorrhage 1/473 (0.21%)",
        "  Neurologic-other 1/473 (0.21%)",
        "  Radiation dermatitis 1/473 (0.21%)"
    ]
}